Literature DB >> 34450238

Pharmaceutical applications of powder-based binder jet 3D printing process - A review.

Koyel Sen1, Tanu Mehta1, Sameera Sansare1, Leila Sharifi2, Anson W K Ma3, Bodhisattwa Chaudhuri4.   

Abstract

Pharmaceutical applications of the 3D printing process have recently matured, followed by the FDA approval of Spritam, the first commercial 3D printed dosage form. Due to being a new technology in the conventional dosage formulation field, there is still a dearth of understanding in the 3D printing process regarding the effect of the raw materials on the printed dosage forms and the plausibility of using this technology in dosage development beyond the conventional ways. In this review, the powder-based binder jet 3D printing (BJ3DP) process and its pharmaceutical applications have been discussed, along with a perspective of the formulation development step. The recent applications of BJ3DP in pharmaceutical dosage development, the advantages, and limitations have further been discussed here. A discussion of the critical formulation parameters that need to be explored for the preformulation study of the solid oral dosage development using the BJ3DP process is also presented.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  3D printing; Binder-jet; Pharmaceutical dosage form; Solid oral dosage form

Mesh:

Substances:

Year:  2021        PMID: 34450238     DOI: 10.1016/j.addr.2021.113943

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  2 in total

1.  Physicochemical Limitations of Capillary Models Applied to High-Concentration Polymer Solutions.

Authors:  David A Schlachter; Martin D Lennox; Basil D Favis; Daniel Therriault; Jason R Tavares
Journal:  ACS Omega       Date:  2022-02-11

2.  In Vitro and In Vivo Bioequivalence Study of 3D-Printed Instant-Dissolving Levetiracetam Tablets and Subsequent Personalized Dosing for Chinese Children Based on Physiological Pharmacokinetic Modeling.

Authors:  Xianfu Li; En Liang; Xiaoxuan Hong; Xiaolu Han; Conghui Li; Yuxi Wang; Zengming Wang; Aiping Zheng
Journal:  Pharmaceutics       Date:  2021-12-22       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.